Regulatory Roundup: WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Regulatory Roundup

According to a release from Rx-360, the international pharmaceutical supply-chain consortium, the World Health Organization has released for comment a draft guideline for the production and control of specified starting materials. The draft, currently released to only a specified audience, defines starting materials as “any substance which is primarily or mainly used as a starting material for the production of an API [active pharmaceutical ingredient], but which itself could be used directly as an API” and notes that the specified starting material should therefore “conform to the existing monograph in a recognized pharmacopeia.” If the material is to be used for API production, however, then the “quality attributes and specifications should be determined by the API manufacturer” and the product’s intended use, according to RX-360’s release on the guideline. Quality control for starting materials should include test for impurities, isomers, residual solvents, and other impurities and take a risk-based approach. The consortium has a full summary on its website.

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here